Using subcutaneous brain tumor mouse models, we consistently showed that in vivo lovastatin treatment also induced DR5 expression in the tumor tissue and inhibited tumor growth; importantly combined treatment with lovastatin and TRAIL resulted in synergistic effects that does not only inhibit tumor growth, reduce tumor volume, but also inhibit Erk activation in U87 cell line. This evidence concerns the gene TNFSF10 and neoplasm.